By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
By expanding its partnership with Ray-Ban, Meta is turning its attention back to building futuristic hardware.
‘What’s more concerning is that people are just waiting and doing nothing’
‘At the end of the day, wherever that data is, it has to be protected’